Desmoid tumor, a rare malignancy of mesenchymal origin, affects a small proportion of the population with an incidence of 2 to 4 patients per million. Also known as “aggressive fibromatosis” or “desmoid-type fibromatosis,” these tumors primarily impact the younger age group. Despite the absence of metastasis, desmoid tumors exhibit local invasion, leading to severe morbidity. The association with the APC gene mutation can result in multifocal DTs, occasionally leading to mortality.The management of desmoid tumors poses a significant challenge due to the lack of a standard treatment approach. Although watchful observation is recommended for asymptomatic desmoid tumors (20% can regress spontaneously), surgical resection has fallen out of favor due to high rates of recurrence. Systemic treatment options have increased with the recent approval of gamma-secretase inhibitor nirogacestat. This activity describes the epidemiology, genetics, clinical presentation, and management of desmoid tumors, providing healthcare professionals with the knowledge and tools necessary to improve patient care for this rare yet complex tumor.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/20406
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Complex General Surgical Oncology, Dermatopathology, General Surgery, Internal Medicine, Medical Oncology